ARTICLE | Company News
Acerus Pharmaceuticals, Aytu deal
May 9, 2016 7:00 AM UTC
Acerus (formerly Trimel Pharmaceuticals Corp.) granted Aytu exclusive, U.S. marketing rights to testosterone replacement therapy Natesto testosterone nasal gel, effective June 30. Acerus will receive an $8 million upfront payment and is eligible for up to $37.5 million in sales milestones. Acerus will be responsible for manufacturing the bioadhesive intranasal gel formulation of testosterone and will receive a tiered supply price. ...